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a b s t r a c t 
Recently, we have disclosed that human KIAA1199 (hKIAA1199) is a hyaluronan (HA) binding protein im- 
plicated in HA depolymerization. Although a murine homologue (mKiaa1199) was previously cloned, no 
information about the function of the molecule was available. Here, we show that cells transfected with 
mKiaa1199 cDNA selectively catabolized HA via the clathrin-coated pit pathway. A glycosaminoglycan- 
binding assay demonstrated the speciﬁc binding of mKiaa1199 to HA. These results were similar to our 
observations with hKIAA1199, although slight differences were found in the peak sizes of the mini- 
mum degradates of HA. We conclude that like hKIAA1199, mKiaa1199 is a hyaladherin, leading to HA 
depolymerization. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical 
Societies. Open access under CC BY-NC-ND license.. Introduction 
Hyaluronan (HA), a major component of the extracellular matrix, 
s ubiquitously present in all vertebrate animals including humans. 
A is a unique linear glycosaminoglycan (GAG) composed of only 
wo sugars, i.e. β(1,3)-linked- d -glucuronic acid and β(1,4)-linked- 
 -acetyl- d -glucosamine, and it provides structural and functional 
ntegrity within the tissue microenvironment to both cells and or- 
ans. HA is rapidly depolymerized under physiological conditions 
rom extra-large native molecules to intermediate-size fragments in 
he extracellular milieu [ 1 ]. HA degradation is enhanced under cer- 
ain pathological conditions, and its lower-molecular-weight prod- 
cts are commonly detected in diseases such as arthritis and cancers 
 2 , 3 ]. Two hyaluronidases (HYAL1 and HYAL2) and a cell surface HA Abbreviations: HA, hyaluronan; GAG, glycosaminoglycan; HYAL, hyaluronidase; 
RF, open reading frame; HEK, human embryonic kidney; FA, ﬂuoresceinamine; CS, 
hondroitin sulfate; DS, dermatan sulfate; Hep, heparin; HS, heparan sulfate; GlcNAc, 
 -acetylglucosamine; HPLC, high performance liquid chromatography; CHC, clathrin 
eavy chain; siRNA, short interfering RNA; FBS, fetal bovine serum; GAPDH, glycer- 
ldehyde 3-phosphate dehydrogenase; PCR, polymerase chain reaction; LDS, lithium 
odecyl sulfate; CPC, cetylpyridinium chloride; PBS, phosphate-buffered saline; PBS-T, 
BS containing 0.05% Tween 20. 
* Corresponding author. Tel.: + 81 465 34 6116; fax: + 81 465 34 3037. 
E-mail address: yoshida.hiroyuki@kanebocos.co.jp (H. Yoshida). 
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ttp://dx.doi.org/10.1016/j.fob.2013.08.003 receptor (CD44) were believed to have the key roles in HA degra- 
dation [ 4 , 5 ]. Recently, however, we have demonstrated that human 
KIAA1199 (hKIAA1199), what ﬁrst had been identiﬁed as a deafness 
gene of unknown function, is clearly capable of binding HA and takes 
part in HA catabolism independently of the CD44 and HYAL enzymes 
in the dermis of healthy skin and the synovium of arthritis patients 
[ 6 ]. 
The hKIAA1199 protein has no substantial homology to HYAL en- 
zymes, HA-binding proteins, or other molecules [ 5 ], lacking both HA- 
link modules and B(X 7 )B HA-binding motifs [ 7 , 8 ], although it has 
two GG domains, one G8 domain expected to take part in extracellu- 
lar ligand binding, and four PbH1 domains believed to be involved in 
polysaccharide hydrolysis [ 9 –11 ]. hKIAA1199 is reportedly expressed 
in a wide range of normal human tissues including brain [ 12 ]. Our pre- 
vious study showed that hKIAA1199 is essential for endogenous HA 
degradation in human skin ﬁbroblasts, and that cells transfected with 
hKIAA1199 cDNA degrade HA through speciﬁc binding with HA [ 6 ]. 
We have also demonstrated that hKIAA1199 is expressed by dermal 
ﬁbroblasts in normal skin and over-expressed by synovial ﬁbrob- 
lasts and tissues from arthritic joints [ 6 ]. All these data suggest that 
KIAA1199 plays a role in HA catabolism under certain physiological 
and pathological conditions in humans, although direct evidence on 
functional analyses of the molecule within tissues is still required. A 
murine homologue ( mKiaa1199 ) of hKIAA1199 has been cloned and 
it is expressed in mouse tissues such as the inner ear [ 13 ]. However, 
no data about functions of the murine molecule have been provided. 
In the current study, therefore, we tried to analyze functional activity an Biochemical Societies.  Open access under CC BY-NC-ND license.

























































































 of mKiaa1199 by expressing this gene in HEK293 cells, and demon-
strated for the ﬁrst time that mKiaa1199 is a hyaladherin that takes
part in HA depolymerization in a manner similar to hKIAA1199. 
2. Materials and methods 
2.1. Cell cultures 
HEK293 cell line (DS Pharma Biomedical) was maintained in Dul-
becco’s modiﬁed Eagle’s medium (Sigma) supplemented with 10%
(vol / vol) FBS, 100 units / ml penicillin and 100 μg / ml streptomycin.
The cells were cultured at 37 ◦C in a humidiﬁed atmosphere contain-
ing 5% CO 2 . 
2.2. Assay for cellular [ 3 H]HA depolymerization 
High-molecular-weight [ 3 H]-labeled HA of > 1000 kDa ([ 3 H]HA)
was prepared as described previously [ 6 ]. Cellular HA depolymer-
ization was assayed by culturing conﬂuent cells in medium con-
taining [ 3 H]HA (40,000 dpm / ml) and by applying the media to a
Sepharose CL-2B (GE Healthcare) column (1 × 60 cm) equilibrated
with 0.5 M NaCl in distilled water. The radioactivity of each frac-
tion was measured by a scintillation counter (Aloka LSC-6100). The
column was calibrated with ﬂuoresceinamine-labeled HA (FA-HA):
FA-HA H1 (1760 kDa), M1 (907 kDa), L1 (197 kDa), S1 (56 kDa), T1
(28 kDa) and U1 (9.8 kDa) (peak top kDa), all of which were purchased
from PG Research. For detection of FA, an excitation wavelength of
490 nm and an emission wavelength of 525 nm were used. 
2.3. Antibodies 
Rat monoclonal antibody against hKIAA1199 was previously de-
veloped using a peptide of CA 762 RYSPHQDADPLKPRE 777 , which cor-
responds to amino acid residues Ala 762 to Glu 777 of hKIAA1199
(GenBank Accession No. NM 018689 ) [ 6 ]. Since mKiaa1199 has
the same amino acid sequence in the molecule (GenBank Acces-
sion No. AB 103331 ), this antibody speciﬁcally recognized both
hKIAA1199 and mKiaa1199. Antibodies against clathrin heavy chain
(CHC), α-adaptin, caveolin-1 and GAPDH were purchased from Santa
Cruz Biotechnology. 
2.4. Immunoblotting 
Cell homogenate supernatants were separated by electrophore-
sis on NuPAGE 4–12% Bis–Tris gels (Invitrogen) and proteins were
transferred onto polyvinylidene diﬂuoride membranes. The mem-
branes were reacted with the antibodies speciﬁc to KIAA1199, CHC,
α-adaptin, caveolin-1 or GAPDH. Then, they were incubated with
horseradish peroxidase-conjugated secondary antibodies: donkey
anti-rat IgG antibody for KIAA1199 (Jackson ImmunoResearch); goat
anti-rabbit IgG antibody for caveolin-1 and GAPDH (DAKO); rab-
bit anti-mouse IgG antibody for α-adaptin (DAKO); and rabbit anti-
goat IgG antibody for CHC (DAKO). Immunoreactive bands were de-
tected by SuperSignal West Pico Chemiluminescent Substrate system
(Thermo Scientiﬁc). 
2.5. Preparations of plasmids and transfectants 
The cDNA of mKiaa1199 was ampliﬁed by PCR using brain cDNA
template (Takara Bio). The authenticity of the cDNA was veriﬁed by se-
quencing using Applied Biosystems 3730xl DNA Analyzer (Life Tech-
nologies). Plasmid was prepared by inserting the cDNA of mKiaa1199
into the expression vector pcDNA3.1( −) (Invitrogen) according to the
manufacture’s protocol. Transient transfection was done using Lipo-
fectamine LTX (Invitrogen), and transfectants were used for the exper-
iments at 48 h after transfection. Stable transfectants of mKiaa1199 inHEK293 cells (mKiaa1199 / HEK293 cells) were prepared by transfec-
tion with the pcDNA3.1( −) vectors containing the mKiaa1199 cDNA
and selection by culturing in medium containing 800 μg / ml of G418
(Sigma). The expression and activity of mKiaa1199 were monitored
by immunoblotting and by the HA-degrading assay, respectively.
The pcDNA3.1( −) vectors containing the hKIAA1199 cDNA and sta-
ble transfectants of hKIAA1199 in HEK293 cells (hKIAA1199 / HEK293
cells), both of which were previously prepared [ 6 ], were used as pos-
itive controls. 
2.6. Identiﬁcation of non-reducing terminal sugar of depolymerized HA
mKiaa1199 / HEK293 cells were cultured in medium containing
[ 3 H]HA (1,000,000 dpm / ml) for 72 h, and radiolabeled products
in the medium were detected on a Sepharose CL-2B column. De-
polymerized [ 3 H]HA in the fractions was precipitated with ethanol,
dissolved in distilled water, and then fractionated on a column
(1 × 107 cm) of Sephadex G-25 (GE Healthcare) after digestion with
β- N -acetylglucosaminidase (Sigma) or sequential digestion with β-
glucuronidase (Sigma) and β- N -acetylglucosaminidase. The elution
position of N -acetylglucosamine (GlcNAc) used as a standard was de-
termined according to previous methods [ 14 ]. 
2.7. Analysis of HA-speciﬁc depolymerization 
mKiaa1199 / HEK239 cells were cultured in medium containing
FA-GAGs: FA-HAs (H1, M1, L1, S1, T1 and U1), chondroitin sulfate A, C
and D (FA-CSA, FA-CSC and FA-CSD), dermatan sulfate (FA-DS), hep-
arin (FA-Hep), and heparan sulfate (FA-HS) (10 μg / ml each). All these
FA-GAGs were purchased from PG Research. After a 72-h incubation
period, the media were harvested and fractionated on a Sepharose
CL-6B (GE Healthcare) column (1 × 35 cm) equilibrated with PBS.
The amounts of FA-GAGs in each fraction were determined by ﬂuo-
rescence counting. 
2.8. Determination of minimum HA size depolymerized from 
high-molecular-weight HA by mKiaa1199 / HEK293 and 
hKIAA1199 / HEK293 cells 
mKiaa1199 / HEK293 and hKIAA1199 / HEK293 cells were cultured
in the medium containing FA-HA H1 (10 μg / ml). After a 72-h culture,
the media were applied to a TSK-GEL G5000PW (7.5 mm inner diame-
ter × 30 cm, Tosoh Corporation) using a 0.05 M CAPS buffer, pH 10.0,
containing 0.8 M NaNO 3 at a ﬂow rate of 0.5 ml / min at 30 
◦C, and
FA-HA was detected by ﬂuorescence counting. Size of the fragments
was determined using FA-HAs including FA-HA H1, M1, L1, S1, T1,
U1 and 3K (2.6 kDa) (PG Research) under the same chromatographic
condition. 
2.9. Co-precipitation of mKiaa1199 protein with GAGs 
mKiaa1199 / HEK293 cells were homogenized in 50 mM phosphate
buffer, pH 6.0 containing a cocktail of proteinase inhibitors (Roche
Diagnostics). Aliquots of the homogenate supernatant (50 μl) were
mixed with 50 μl of 1 mg / ml aqueous solutions of non-labeled GAGs:
CSA, CSC, CSD, DS, Hep, HS, HA-H2 (1452 kDa), HA-M2 (1039 kDa),
HA-L2 (219 kDa), HA-S2 (52 kDa) and HA-T2 (28 kDa) (PG Research)
or H 2 O (negative control). They were incubated for 1 h at 37 
◦C,
and 1% cetylpyridinium chloride (CPC) (ﬁnal concentration; wt / vol)
was added to the GAG / lysate mixtures. The precipitates were elec-
trophoresed on NuPAGE 4–12% Bis–Tris gels (Invitrogen) under re-
ducing conditions and immunoblotted with anti-KIAA1199 mono-
clonal antibody. 






















































Fig. 1. HA depolymerization by mKiaa1199 transfectants and determination of HA 
cleavage sites . (A) HEK293 cells were transiently transfected with empty vector (Mock) 
or vector containing hKIAA1199 or mKiaa1199 cDNA. The expression of hKIAA1199 
and mKiaa1199 proteins in each transfectant was assessed by immunoblotting using 
anti-KIAA1199 monoclonal antibody (inset). Mock and mKiaa1199 transfectants were 
incubated with [ 3 H]HA for 48 h, and HA depolymerization was then examined by 
size exclusion chromatography. GAPDH, a loading control. (B) Determination of the 
non-reducing terminal sugar of depolymerized HA. [ 3 H]HA fragments obtained from 
the culture media were incubated with β- N -acetylglucosaminidase (open circles) or β- 
glucuronidase followed by incubation with β- N -acetylglucosaminidase (closed circles), 
and then applied to Sephadex G-25 column chromatogram. .10. RNA interference 
Two different siRNAs for CHC , caveolin-1 and α-adaptin , and non- 
ilencing control siRNAs were purchased from Invitrogen. The se- 
uences of the siRNAs are described previously [ 6 ]. siRNAs were 
ransfected into cells using Lipofectamine RNAiMAX (Invitrogen). 
.11. Immunoﬂuorescence microscopy for mKiaa1199 in 
Kiaa1199 / HEK293 cells 
For double immunostaining of mKiaa1199 and CHC, mKiaa1199 / 
EK293 cells were grown on glass multi-chamber slides (BD 
iosciences) to 70–80% conﬂuence, and ﬁxed with 4% (wt / vol) 
araformaldehyde in PBS. After washing in PBS containing 0.05% (vol / 
ol) Tween 20 (PBS-T), the cells were reacted with rat anti-KIAA1199 
onoclonal antibody conjugated to Alexa-Flour 488 and goat anti- 
HC antibody conjugated to Alexa-Flour 555. The samples were coun- 
erstained with TO-PRO-3 (Invitrogen) and mounted in vectashield 
Vector). As for controls, samples were reacted with non-immune IgG 
onjugated to Alexa-Flours. These samples were observed using Zeiss 
SM 510 confocal microscope (Carl Zeiss). 
.12. Cellular distribution of exogenously added HA in 
Kiaa1199 / HEK293 cells 
The cells on glass multi-chamber slides were incubated in the pres- 
nce or absence of 0.1 mg / ml biotin-labeled high-molecular-weight 
A of 1410 kDa (PG research) at 37 ◦C for 1 h, and then ﬁxed with 4% 
wt / vol) paraformaldehyde in PBS. After washing in PBS-T, incubation 
ith streptavidin conjugated to Alexa-Fluor 488 (Invitrogen), and nu- 
lear counterstaining with TO-PRO-3, they were observed using Zeiss 
SM 510 confocal microscope. As for a control, the cells were incu- 
ated with biotin-labeled high-molecular-weight HA digested with 
treptomyces hyaluronidase (Seikagaku Corporation), followed by the 
mmunostaining described above. 
. Results and discussion 
.1. Cells transfected with mKiaa1199 cDNA acquire HA-degrading 
apability 
The overall homology of the coding regions between mKiaa1199 
nd hKIAA1199 proteins was 91% identical, and four PbH1 domains, 
hich may be involved in polysaccharide hydrolysis [ 10 , 11 ], are com- 
letely conserved ( Supplementary Fig. 1 ). To examine the implication 
f mKiaa1199 in HA depolymerization, we transfected HEK293 cells, 
 cell line with no HA depolymerizing activity, with a full-length 
Kiaa1199 cDNA. As shown in Fig. 1 A, mKiaa1199 protein was ob- 
erved at exactly the same position as hKIAA1199 of 150 kDa by 
mmunoblotting. The mKiaa1199 transfectants depolymerized ex- 
genous [ 3 H]HA to intermediate-size fragments, and released the 
atabolites into the medium, whereas mock transfectants showed 
egligible HA depolymerization ( Fig. 1 A). The mKiaa1199-mediated 
epolymerization of HA seems to be independent of HYAL1 and 
YAL2, as both molecules were expressed at negligible levels in 
EK293 cells [ 6 ]. The non-reducing terminal sugar of the fragments 
as determined to be glucuronic acid by incubation of the depoly- 
erized [ 3 H]HA with β- N -acetylglucosaminidase or β-glucuronidase 
ollowed by β- N -acetylglucosaminidase ( Fig. 1 B). This ﬁnding indi- 
ates that HA is cleaved at the β-endo- N -acetylglucosamine bonds. 
aken together, the evidence suggests that cells which overexpress 
Kiaa1199 depolymerize HA to intermediate-size fragments in an 
ndo- β- N -acetylglucosaminidase-dependent manner and accumu- 
ate the catabolites extracellularly. These observations are consistent 
ith the results previously reported with hKIAA1199 [ 6 ]. 3.2. Stable transfectants of mKiaa1199 in HEK293 cells selectively bind 
and degrade HA species of different molecular weights 
We ﬁrst prepared stable transfectants of mKiaa1199 in HEK293 
cells (mKiaa1199 / HEK293 cells), and examined the activity of 
mKiaa1199 for binding to and depolymerization of HA. When 
mKiaa1199 protein isolated from the transfectants were incubated 
with HA or other GAGs (CSA, CSC, CSD, DS, Hep, and HS), and then pre- 
cipitated with CPC, mKiaa1199 was co-precipitated with HA, whereas 
the other GAGs showed negligible precipitates ( Fig. 2 A). In addi- 
tion, we observed co-precipitation of mKiaa1199 with various HA 
species with different molecular weights (HA-H2, 1452 kDa; HA-M2, 
1039 kDa; HA-L2, 219 kDa; HA-S2, 52 kDa; HA-T2, 28 kDa) ( Fig. 2 B). 
Then, we further studied degradation of FA-labeled HA (FA-HA) added 
to mKiaa1199 / HEK293 cells. As shown in Fig. 3 A, the cells selectively 
digested several FA-HA species with different molecular weights, i.e. 
FA-HA H1 (1760 kDa), M1 (907 kDa), L1 (197 kDa), S1 (56 kDa), T1 
(28 kDa) and U1 (9.8 kDa) (peak top kDa), into fragments of a con- 
stant size, whereas they showed no digestion of other FA-GAGs (CSA, 
CSC, CSD, DS, Hep, and HS). Meanwhile, no HA-degrading activity 
was detected in cell lysates from mKiaa1199 / HEK293 cells (data not 
shown). All these data on HA speciﬁc binding and depolymerization 
of mKiaa1199 match our previous ﬁndings with hKIAA1199 cells [ 6 ]. 
Interestingly, however, the peak size of minimum degradates depoly- 
merized from FA-HA H1 by mKiaa1199 / HEK293 cells (about 4.1 kDa, 
corresponding to ten disaccharide units) differed slightly from the 
peak size obtained by hKIAA1199 / HEK293 cells under the same con- 
dition (about 3.3 kDa, corresponding to eight disaccharide units) ( Fig. 
3 B and C). In particular, a low-molecular-weight shoulder ( < 2 kDa) 
was observed in the elution proﬁle of the fragments depolymerized by 
mKiaa1199 ( Fig. 3 B). To examine how the mKiaa1199 expression lev- 
els affected the sizes of the HA fragments, we performed a time course 
digestion of HA by stable transfectants of mKiaa1199 with maximal 
mKiaa1199 expression (mKiaa1199 / HEK293) or low mKiaa1199 ex- 
pression (mKiaa1199 / HEK293-L) ( Supplementary Fig. 2 A) and then 
measured the fragment sizes. As shown from Supplementary Fig. 
2 B and C, the peak size of the HA degradates from the mKiaa1199 / 
HEK293-L cells (about 17.9 kDa) was larger than the peak size of the 
HA degradates from the mKiaa1199 / HEK293 cells (about 4.1 kDa). It 
H. Yoshida et al. / FEBS Open Bio 3 (2013) 352–356 355 
Fig. 2. HA-speciﬁc binding of recombinant mKiaa1199 protein expressed in 
mKiaa1199 / HEK293 cells. (A) Binding assay of mKiaa1199 protein to different GAGs. 
Lysates of mKiaa1199 / HEK293 cells were incubated with H 2 O (negative control) or 
unlabeled GAGs including HA (HA-H2), CSA, CSC, CSD, DS, Hep and HS. The samples 
were precipitated with CPC, and analyzed by immunoblotting with anti-KIAA1199 an- 
tibody. (B) Binding of mKiaa1199 to HA species with different molecular sizes. The 
lysates were incubated with H 2 O (negative control) or HA with different sizes includ- 
ing HA-H2, HA-M2, HA-L2, HA-S2 and HA-T2, and then subjected to immunoblotting 














































Fig. 3. HA-speciﬁc depolymerization by mKiaa1199 / HEK293 cells, and peak size of 
the minimum degradates . (A) Depolymerization of HA with different molecular sizes 
by mKiaa1199 / HEK293 cells. Control HEK293 (open circles) and mKiaa1199 / HEK293 
cells (closed circles) were cultured for 72 h with HA species with different molecular 
weights (FA-HA H1, M1, L1, S1, T1 or U1) or FA-GAGs other than HA (FA-CSA, FA-CSC, 
FA-CSD, FA-DS, FA-Hep and FA-HS). Depolymerization of these GAGs in the media was 
determined by chromatography on a Sepharose CL-6B column. Dotted lines indicate 
GAG without incubation. (B) HPLC pattern of minimum degradates depolymerized from 
FA-HA H1 by mKiaa1199 / HEK293 (chain line) and hKIAA1199 / HEK293 (dotted line) 
cells. The solid line indicates FA-HA H1 without incubation. (C) Peak sizes of minimum 
fragments from FA-HA H1 depolymerized by mKiaa1199 / HEK293 and hKIAA1199 / 
HEK293 cells. Molecular weight of the fragments was determined using the following 















 thus appears that mKiaa1199 expression levels may affect the sizes of
the degradates. We were unable, however, to rule out the possibility
that the degradates from the mKiaa1199 / HEK293-L cells were not
end products. This possibility must be expressly allowed, given that
mKiaa1199 / HEK293-L cells failed to completely degrade the high-
molecular-weight HA after the 72 h incubation in our time course
experiment. Although the reason why the expression of mKiaa1199
results in the HA degradation product with slightly different molec-
ular size compared to that by hKIAA1199 is not clear, it may be in-
teresting to speculate that this is due to less sequence homology of
mouse G8 domain (82% to that of hKIAA1199), which may be involved
in extracellular ligand binding [ 10 ]. 
3.3. HA is catabolized by mKiaa1199 via the clathrin-coated pit 
pathway 
Since our earlier study suggested the implication of the clathrin-
coated vesicles or early endosomes in hKIAA1199-mediated HA de-
polymerization [ 6 ], we assessed the possible involvement of the
clathrin-coated pit pathway in mKiaa1199-mediated HA degrada-
tion. As shown in Fig. 4 A and B, HA degradation was reduced in
mKiaa1199 / HEK293 cells when the expression of CHC and α-adaptin
subunit of AP-2, an adaptor protein complex functioning as a ma-
jor organizer of clathrin coats, was knocked down by siRNAs. In
contrast, the knockdown of caveolin-1, a protein involved in the
caveolae pathway, caused no changes in mKiaa1199-mediated HA
degradation ( Fig. 4 C). Immunohistochemistry revealed the localiza-
tion of mKiaa1199 in vesicles in peripheral regions occasionally close
to CHC-positive vesicles ( Fig. 4 D), but no ﬂuorescence was observed
by non-immune IgG (data not shown). High-molecular-weight HA
added to the mKiaa1199 / HEK293 cells was shown in some vesicles
in the cell periphery (Fig. E), but no ﬂuorescence was detected by
incubation with Streptomyces hyaluronidase-digested HA (data not
shown). These results suggest that HA is endocytosed via clathrin-
coated pits and degraded in vesicles in the periphery of mKiaa1199 /
HEK293 cells. We also conﬁrmed that the levels of CHC and α-adaptin
expression were essentially identical between mKiaa1199 / HEK293
and hKIAA1199 / HEK293 cells ( Supplementary Fig. 3 ). This matching
of expression patterns suggests that CHC and α-adaptin are unlikely
to be involved in the size determination of the end products. 
The current study provides the ﬁrst evidence that like hKIAA1199,
mKiaa1199 has the capability of binding speciﬁcally to HA, leading to
HA depolymerization. The HA depolymerization by mKiaa1199 was
almost identical to that by hKIAA1199, although slight differences
were found in the elution proﬁles and peak sizes of the minimum
degradates of HA. Note also that, like the cell lysates of hKIAA1199
[ 6 ], the cell lysates of stable transfectants of mKiaa1199 lacked HA de-
polymerizing activity. hKIAA1199 is reported to be widely expressed
in human organs including the brain, skin, lung, testis and ovary, but
it is notably absent in the liver [12]. We observed a similar tissue dis-
tribution of mRNA expression of mKiaa1199 by real-time PCR usingcommercially available mouse tissue RNA library (Okada et al., un-
published data). Mouse Hyal1 and Hyal2 are also broadly expressed
in various mouse tissues, with peak expression in the liver and neg-
ligible expression in the brain [ 15 , 16 ]. The tissue expression patterns
of these mouse molecules suggest that the mKiaa1199 and Cd44 /
Hyals systems may have different or cooperative roles in the phys-
iological HA catabolism in mouse organs. Previous studies showed
that mice deﬁcient in the Hyal1 or Hyal2 gene exhibit no signiﬁcant
accumulation of HA locally within tissues [ 16 , 17 ]. These observations
tempt us to speculate that mKiaa1199 might degrade HA in a com-
pensatory fashion in these mice. KIAA1199 was originally reported
as a candidate gene for the congenital or childhood-onset bilateral
nonsyndromic sensorineural hearing loss [ 13 ]. In addition, our pre-
vious study demonstrated that two mutations at the Arg 187 residue
(R187C and R187H) out of the four reported mutations result in loss






























vig. 4. Clathrin-speciﬁc HA depolymerization and cellular localization of mKiaa1199 
n mKiaa1199 / HEK293 cells. (A–C) Changes in HA depolymerization in mKiaa1199 / 
EK293 cells by knockdown of CHC (A), α-adaptin (B) or caveolin-1 (C) with siRNAs. 
s for controls, cells were transfected with control non-silencing siRNA. After incu- 
ation of the cells with [ 3 H]HA for 24 h, HA fragments in the media were analyzed 
y size exclusion chromatography. Efﬁciency of the knockdown was evaluated by im- 
unoblotting (insets). Representative data from two siRNAs are shown. (D) Double 
mmunostaining of mKiaa1199 (green) and CHC (red) with anti-KIAA1199 and anti- 
HC antibodies in mKiaa1199 / HEK293 cells. The inset shows a high-power view of 
he boxed area. Dotted lines show the plasma membrane. N, nucleus. Scale bar, 5 μm; 
cale bar for inset, 1 μm. (E) HA localization in mKiaa1199 / HEK293 cells after incu- 
ation with biotin-labeled HA, followed by reaction with streptavidin conjugated to 
lexa-Fluor 488. Arrows, HA-positive structures; N, nucleus. Scale bar, 5 μm. (For in- 
erpretation of the references to color in this ﬁgure legend, the reader is referred to the 
eb version of this article.) 
f the HA depolymerization [ 6 ]. Since mKiaa1199 is highly expressed 
n the mouse inner ear [ 13 ] and the Arg 187 residue in the molecule is 
onserved in both humans and mice ( Supplementary Fig. 1 ), the mu- 
ations at this residue in mKiaa1199 may be related to hearing loss in 
ice. hKIAA1199 is highly expressed in rheumatoid or osteoarthritic 
ynovium [ 6 ], human cancer tissues such as carcinomas of the colorec- 
um and stomach [ 12 , 18 ] and also skin ﬁbroblasts from a patient with 
erner syndrome, an adult-onset progeroid disease [ 12 ], although 
hese studies on cancer tissues and Werner syndrome provided no 
ata on the involvement in HA catabolism or the biological func- 
ions. Since the present study has disclosed that mKiaa1199 shares 
he functional activity with hKIAA1199, development of knockout 
nd transgenic mice and disease models using the mice would be 
seful to study roles of this gene in physiological HA catabolism in ivo and investigate detailed pathogenesis of the KIAA1199-linked human diseases such as hearing loss, arthritis and cancers. 
Supplementary material 
Supplementary material associated with this article can be found, 
in the online version, at doi:10.1016 / j.fob.2013.08.003 . 
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